Tags

Type your tag names separated by a space and hit enter

Detection of low levels of SARS-CoV-2 RNA from nasopharyngeal swabs using three commercial molecular assays.
J Clin Virol. 2020 07; 128:104387.JC

Abstract

In response to the COVID-19 pandemic, commercial molecular assays for SARS-CoV-2 testing have been rapidly developed and broadly deployed in laboratories worldwide. Although these assays have been reported to correlate well, we sought to compare the Xpert® Xpress SARS-CoV-2 to the cobas® SARS-CoV-2 or the Lightmix® Modular SARS and Wuhan CoV E-gene assay for nasopharyngeal (NP) swabs with low levels of SARS-CoV-2 RNA. Thirty-seven NP swabs were studied, including 10 samples with a moderate cycle threshold (Ct) between 30-33.9, and 22 with Ct≥34, and 5 negative for SARS-CoV-2. Overall concordance on initial comparison was 86.5 % (32/37), which was 100 % concordance for samples with Ct values ranging between 30-33.9. Discordance amongst samples showing a Ct ≥34 was 22.7 % (5/22). Endpoint value analysis on the Xpress SARS-CoV-2 within the discordant samples noted two with an endpoint value >5, which were detected by the cobas® or Lightmix®. Testing of SARS-CoV-2 on the three commercial assays was comparable for NP swabs with moderate Ct values, while high Ct values were less concordant. Importantly, analysis of Xpert® endpoint values improved interpretation of discrepant results.

Authors+Show Affiliations

Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. Electronic address: clowe@providencehealth.bc.ca.Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada.Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.

Pub Type(s)

Journal Article
Validation Study

Language

eng

PubMed ID

32380382

Citation

Lowe, Christopher F., et al. "Detection of Low Levels of SARS-CoV-2 RNA From Nasopharyngeal Swabs Using Three Commercial Molecular Assays." Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, vol. 128, 2020, p. 104387.
Lowe CF, Matic N, Ritchie G, et al. Detection of low levels of SARS-CoV-2 RNA from nasopharyngeal swabs using three commercial molecular assays. J Clin Virol. 2020;128:104387.
Lowe, C. F., Matic, N., Ritchie, G., Lawson, T., Stefanovic, A., Champagne, S., Leung, V., & Romney, M. G. (2020). Detection of low levels of SARS-CoV-2 RNA from nasopharyngeal swabs using three commercial molecular assays. Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, 128, 104387. https://doi.org/10.1016/j.jcv.2020.104387
Lowe CF, et al. Detection of Low Levels of SARS-CoV-2 RNA From Nasopharyngeal Swabs Using Three Commercial Molecular Assays. J Clin Virol. 2020;128:104387. PubMed PMID: 32380382.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Detection of low levels of SARS-CoV-2 RNA from nasopharyngeal swabs using three commercial molecular assays. AU - Lowe,Christopher F, AU - Matic,Nancy, AU - Ritchie,Gordon, AU - Lawson,Tanya, AU - Stefanovic,Aleksandra, AU - Champagne,Sylvie, AU - Leung,Victor, AU - Romney,Marc G, Y1 - 2020/04/28/ PY - 2020/04/22/received PY - 2020/04/25/accepted PY - 2020/5/8/pubmed PY - 2020/7/7/medline PY - 2020/5/8/entrez KW - COVID-19 KW - Cobas KW - Endpoint values KW - Xpert SP - 104387 EP - 104387 JF - Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology JO - J Clin Virol VL - 128 N2 - In response to the COVID-19 pandemic, commercial molecular assays for SARS-CoV-2 testing have been rapidly developed and broadly deployed in laboratories worldwide. Although these assays have been reported to correlate well, we sought to compare the Xpert® Xpress SARS-CoV-2 to the cobas® SARS-CoV-2 or the Lightmix® Modular SARS and Wuhan CoV E-gene assay for nasopharyngeal (NP) swabs with low levels of SARS-CoV-2 RNA. Thirty-seven NP swabs were studied, including 10 samples with a moderate cycle threshold (Ct) between 30-33.9, and 22 with Ct≥34, and 5 negative for SARS-CoV-2. Overall concordance on initial comparison was 86.5 % (32/37), which was 100 % concordance for samples with Ct values ranging between 30-33.9. Discordance amongst samples showing a Ct ≥34 was 22.7 % (5/22). Endpoint value analysis on the Xpress SARS-CoV-2 within the discordant samples noted two with an endpoint value >5, which were detected by the cobas® or Lightmix®. Testing of SARS-CoV-2 on the three commercial assays was comparable for NP swabs with moderate Ct values, while high Ct values were less concordant. Importantly, analysis of Xpert® endpoint values improved interpretation of discrepant results. SN - 1873-5967 UR - https://www.unboundmedicine.com/medline/citation/32380382/Detection_of_low_levels_of_SARS_CoV_2_RNA_from_nasopharyngeal_swabs_using_three_commercial_molecular_assays_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1386-6532(20)30129-3 DB - PRIME DP - Unbound Medicine ER -